Keith T Flaherty

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Science · 2020-09-29 · 771 citations

Understanding humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for improving diagnostics, therapeutics, and vaccines. Deep serological profiling of 232 coronavirus disease 2019 (COVID-19) patients and 190 pre-COVID-19 era controls using VirScan revealed more than 800 epitopes in the SARS-CoV-2 proteome, including 10 epitopes likely recognized by neutralizing antibodies. Preexisting antibodies in controls recognized SARS-CoV-2 ORF1, whereas only COVID-…

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

Cell · 2020 · 581 citations

Crucial transitions in cancer-including tumor initiation, local expansion, metastasis, and therapeutic resistance-involve complex interactions between cells within the dynamic tumor ecosystem. Transformative single-cell genomics technologies and spatial multiplex in situ methods now provide an opportunity to interrogate this complexity at unprecedented resolution. The Human Tumor Atlas Network (HTAN), part of the National Cancer Institute (NCI) Cancer Moonshot Initiative, will establish a clinic…

Data from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

2025-10-15

<div>AbstractPurpose:<p>Liquid biopsies with circulating tumor DNA (ctDNA) analysis are increasingly being utilized as a noninvasive approach to identify actionable genomic alterations in advanced/metastatic cancers. In this study, we report the correlation between ctDNA analysis of plasma samples collected from patients enrolled in the NCI-MATCH trial and tumor tissue–based sequencing.</p>Experimental Design:<p>We analyzed plasma samples collected from patients enrolled…

Supplementary Table 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

2025-10-15

<p>Supplementary Table 5. List of alterations of interest that were discordant between tissue and plasma in patients enrolled based on central testing.</p>

Supplementary Table 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

2025-10-15

<p>Supplementary Table 1. Prioritized subprotocols of NCI-MATCH that were included in plasma analysis.</p>